Holen Sie sich die Stockscreener-App
15.78
1.07%
-0.14
Handel nachbörslich:
15.78
Schlusskurs vom Vortag:
$15.92
Offen:
$15.98
24-Stunden-Volumen:
215.46K
Relative Volume:
0.49
Marktkapitalisierung:
$5.63B
Einnahmen:
$5.21B
Nettoeinkommen (Verlust:
$-211.00M
KGV:
-25.54
EPS:
-0.6179
Netto-Cashflow:
$861.30K
1W Leistung:
-2.78%
1M Leistung:
-0.44%
6M Leistung:
-2.78%
1J Leistung:
+39.50%
1-Tages-Spanne:
$15.66
$15.98
1-Wochen-Bereich:
$15.66
$16.34
52-Wochen-Spanne:
$11.22
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
15.78 | 5.68B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
436.65 | 155.16B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.75 | 40.68B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.69 | 33.06B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.16 | 31.30B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.10 | 30.18B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Evercore ISI Group Maintains Bausch + Lomb (BLCO) Outperform Recommendation - MSN
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Medical Devices & SuppliesSpecialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest - Yahoo! Finance Canada
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb CEO, R&D chief to join Goldman Sachs health-care chat - Stock Titan
BLCO.CA Stock Price, Quote & Chart | BAUSCH + LOMB CORP (TSX:BLCO) - ChartMill
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results - BioSpace
Board re-elected, exec pay backed: inside Bausch + Lomb’s 2026 vote - Stock Titan
Bausch + Lomb (BLCO) investors approve board, pay and PwC auditor at 2026 meeting - Stock Titan
Bausch + Lomb unveils PreserVision AREDS3 eye vitamins in the U.S. - Mass Market Retailers
New eye vitamin targets leading cause of vision loss in older Americans - Stock Titan
How Investors May Respond To Bausch + Lomb (BLCO) Surgical Launch and EBITDA Momentum - Yahoo Finance
Bausch + Lomb Corporation (BLCO): Carl C. Icahn Likes This Stock - Insider Monkey
Brent Saunders: Healthcare Innovation Leader, Global Pharmaceutical Executive, and Bausch + Lomb CEO - BBN Times
BLCO (BLCO) CFO has 63,938 shares withheld to cover RSU taxes - Stock Titan
Tax withholding trims Bausch & Lomb (NYSE: BLCO) EVP share count - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP has 8,673 shares withheld for RSU taxes - Stock Titan
Bausch & Lomb (BLCO) executive reports 11,970-share RSU tax withholding on Form 4 - Stock Titan
Bausch + Lomb launches Bi-Blade+ vitrectomy cutter in Europe - Investing.com
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe – Company Announcement - Financial Times
June 1 webinar to detail lens material not seen in 25 years - Stock Titan
Q2 EPS Estimates for Bausch + Lomb Lifted by HC Wainwright - MarketBeat
Bausch & Lomb Earnings: Vision Care Resilience and Pharmaceutical Rebound Lead Off 2026 - Morningstar Canada
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
What Bausch + Lomb (BLCO)'s Upgraded 2026 Outlook and Narrowing Losses Mean For Shareholders - Yahoo Finance
Bausch & Lomb (BLCO) director receives 1,415 restricted share units - Stock Titan
Director at Bausch & Lomb (NYSE: BLCO) granted 1,611 RSUs - Stock Titan
Director John Paulson receives 1,375 RSUs in Bausch & Lomb (NYSE: BLCO) - Stock Titan
Bausch & Lomb (BLCO) director receives 1,375 restricted share units - Stock Titan
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $16 - Moomoo
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Align Tech (ALGN) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch & Lomb Corp Q1 2026 Financial Results and Risk Factors – Form 10-Q Highlights - Minichart
BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating - 富途牛牛
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16 - 富途牛牛
Deutsche Bank Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $16 - 富途牛牛
Bausch + Lomb (NYSE:BLCO) Issues Earnings Results - MarketBeat
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting - BioSpace
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $21 - 富途牛牛
Bausch + Lomb Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
From dry eye to glaucoma, 40+ Bausch + Lomb studies head to Denver - Stock Titan
BofA raises Bausch & Lomb stock price target on earnings beat - Investing.com UK
BofA raises Bausch & Lomb stock price target on earnings beat By Investing.com - Investing.com South Africa
Bausch & Lomb Corp (BLCO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Bausch + Lomb Q1 Earnings Call Highlights - Yahoo Finance
Evercore ISI cuts Bausch & Lomb stock price target on growth outlook - Investing.com India
Evercore ISI cuts Bausch & Lomb stock price target on growth outlook By Investing.com - Investing.com South Africa
Bausch & Lomb 10-Q: Revenue $1,244M, Loss per Share $(0.20) - TradingView
Bausch + Lomb (BLCO) Q1 2026 revenue rises to $1.24B as loss narrows - Stock Titan
Earnings call transcript: Bausch + Lomb exceeds Q1 2026 earnings expectations By Investing.com - Investing.com Australia
Bausch + Lomb Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):